patient subgroup...
HER2 positive
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
la/mBC - HER2 positive - 2nd Line (L2), HER inhibitor , meta-analysis of study results
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
efficacy endpoints 00 deaths (OS) 0.85 [0.72, 1.00]< 1 71% 8 studies (8/-) 97.4 % some concern not evaluable moderate crucial - iDFS 0.67 [0.50, 0.90]< 1 0% 1 study (1/-) 99.6 % NA not evaluable important - progression or deaths (PFS) 0.73 [0.63, 0.86]< 1 67% 7 studies (7/-) 100.0 % some concern not evaluable moderate important - RFS/DFS 0.63 [0.47, 0.85]< 1 0% 1 study (1/-) 99.9 % NA not evaluable important - DOR 0.50 [0.34, 0.73]< 1 0% 2 studies (2/-) 100.0 % some concern not evaluable moderate non important - objective responses (ORR) 1.45 [1.20, 1.76]> 1 4% 6 studies (6/-) 100.0 % some concern not evaluable moderate non important - safety endpoints 00 AE leading to treatment discontinuation (any grade) 1.38 [0.80, 2.36]< 1 0% 2 studies (2/-) 12.3 % some concern not evaluable moderate non important - AE (grade 3-4) endpoints 00 Anaemia AE (grade 3-4) 0.74 [0.36, 1.54]< 1 0% 2 studies (2/-) 78.8 % some concern not evaluable moderate non important - Asthenia AE (grade 3-4) 0.89 [0.29, 2.72]< 1 5% 2 studies (2/-) 58.0 % some concern not evaluable moderate non important - Back pain AE (grade 3-4) 0.98 [0.02, 50.38]< 1 0% 1 study (1/-) 50.4 % NA not evaluable non important - Constipation AE (grade 3-4) 1.00 [0.17, 5.83]< 1 0% 2 studies (2/-) 49.9 % some concern not evaluable moderate non important - Decreased appetite AE (grade 3-4) 0.99 [0.14, 7.14]< 1 0% 2 studies (2/-) 50.3 % some concern not evaluable moderate non important - Diarrhoea AE (grade 3-4) 1.58 [0.65, 3.83]< 1 16% 2 studies (2/-) 15.4 % some concern not evaluable moderate non important - Fatigue AE (grade 3-4) 1.53 [0.67, 3.46]< 1 0% 2 studies (2/-) 15.6 % some concern not evaluable moderate non important - Headache AE (grade 3-4) 0.99 [0.06, 16.02]< 1 0% 2 studies (2/-) 50.2 % some concern not evaluable moderate non important - Nausea AE (grade 3-4) 1.20 [0.27, 5.40]< 1 9% 2 studies (2/-) 40.5 % some concern not evaluable moderate non important - Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4) 0.98 [0.29, 3.27]< 1 0% 1 study (1/-) 51.5 % NA not evaluable non important - Pyrexia AE (grade 3-4) 0.75 [0.09, 6.50]< 1 0% 2 studies (2/-) 60.1 % some concern not evaluable moderate non important - Rash AE (grade 3-4) 0.48 [0.02, 14.79]< 1 0% 1 study (1/-) 65.9 % NA not evaluable non important - Stomatitis AE (grade 3-4) 1.55 [0.16, 15.45]< 1 0% 2 studies (2/-) 35.5 % some concern not evaluable moderate non important - Vomiting AE (grade 3-4) 0.60 [0.14, 2.57]< 1 0% 2 studies (2/-) 75.4 % some concern not evaluable moderate non important - Weight decreased AE (grade 3-4) 0.98 [0.06, 16.11]< 1 0% 1 study (1/-) 50.6 % NA not evaluable non important -
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies;
published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE.
Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.